Evolus, Inc.
NASDAQ:EOLSDrug Manufacturers - Specialty & Generic
-$0.14 today
- Market cap
- $467.95M
- Beta
- 1.33
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.67
Volume 0.80M
Average 0.86M
EOLS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Evolus, Inc.NASDAQ: EOLS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -9.4%
Operating margin was -9.4% in Q1 FY2026, up 12.8 pp from a year earlier. On a trailing-twelve-month basis it was -9.6%, up 5.2 pp year over year. Over 3 fiscal years it widened by 31.3 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of 4.6% for the fiscal year ending Dec 2026, up from -12.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -9.4%-9.1 pp QoQ
- Last fiscal yearDec 2025
- -12.7%+0.3 pp YoY
- LTMMar 2026
- -9.6%+5.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -12.7%
- Year-over-year change
- +0.3pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -12.7% | +0.3pp |
| FY2024 | 2024-12-31 | -12.9% | +11.4pp |
| FY2023 | 2023-12-31 | -24.4% | +19.6pp |
| FY2022 | 2022-12-31 | -44.0% | +0.6pp |
| FY2021 | 2021-12-31 | -44.6% | — |
Operating Margin vs competitors
How EOLS compares with its peers on the latest reported figures
No competitor Operating Margin figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M |
| Cost of Revenue | 43.53M | 58.84M | 61.56M | 83.97M | 104.41M |
| Gross Profit | 56.14M | 89.77M | 140.53M | 182.3M | 192.76M |
| Gross Margin | 56.3% | 60.4% | 69.5% | 68.5% | 64.9% |
| Research & Development | 2.06M | 6.74M | 15.43M | 9.17M | 9.58M |
| Selling, General & Admin | 112.07M | 141.84M | 164.94M | 198.03M | 220.79M |
| Operating Expenses | 100.54M | 155.1M | 189.76M | 216.72M | 230.36M |
| Depreciation & Amortization | 6.31M | 3.72M | 5.87M | 6.02M | 8.74M |
| EBITDA | (39.06M) | (53.85M) | (41.81M) | (25M) | (22.53M) |
| EBITDA Margin | -39.2% | -36.2% | -20.7% | -9.4% | -7.6% |
| Operating Income | (44.41M) | (65.33M) | (49.23M) | (34.41M) | (37.6M) |
| Operating Margin | -44.6% | -44.0% | -24.4% | -12.9% | -12.7% |
| Interest Income | 1K | 119K | 860K | 3.26M | 1.93M |
| Interest Expense | 1.4M | 9.1M | 13.83M | 18.74M | 19.69M |
| Other Income / Expenses | (2.36M) | (8.99M) | (12.28M) | (15.35M) | (13.36M) |
| Income Before Tax | (46.77M) | (74.32M) | (61.51M) | (49.76M) | (50.96M) |
| Pre-Tax Margin | -46.9% | -50.0% | -30.4% | -18.7% | -17.1% |
| Income Tax Expense | 42K | 95K | 176K | 664K | 677K |
| Net Income | (46.81M) | (74.41M) | (61.69M) | (50.42M) | (51.64M) |
| Net Margin | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% |
| EPS (Basic) | (0.94) | (1.33) | (1.08) | (0.81) | (0.80) |
| EPS (Diluted) | (0.94) | (1.33) | (1.08) | (0.81) | (0.80) |
| Weighted Avg Shares | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M |
| Weighted Avg Shares (Diluted) | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M |
Evolus, Inc.
NASDAQ:EOLS
Intrinsic Alpha fair value
Locked
Current Price
$7.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.